Medical Pharmacology: Chapter 39 — Pharmacological Management of Coagulation Disorders -- Module 6 — Thrombolytic Therapy and Procoagulant Agents

Chapter 39 — Pharmacological Management of Coagulation Disorders — Module 6 — Thrombolytic Therapy and Procoagulant Agents
Tier: CC — Core Concepts

1. The fibrinolytic system is activated when a serine protease cleaves an inactive zymogen circulating in plasma, converting it to its active form, which then degrades fibrin clots. Which of the following correctly identifies the zymogen, the active enzyme it becomes, and the primary activator responsible for this conversion?

A) Fibrinogen is converted to fibrin by thrombin, which is activated by factor Xa
B) Plasminogen is converted to plasmin by tissue plasminogen activator (tPA), which preferentially activates plasminogen when it is bound to fibrin
C) Prothrombin is converted to thrombin by the prothrombinase complex, which includes factor Xa and factor Va on a phospholipid surface
D) Factor X is converted to factor Xa by the intrinsic tenase complex, consisting of factors IXa and VIIIa
E) von Willebrand factor is cleaved by ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motifs), releasing it from endothelial storage granules

ANSWER: B

Rationale:

Option B is correct. Plasminogen is the inactive zymogen that circulates in plasma; tissue plasminogen activator (tPA) cleaves a single arginine-valine bond in plasminogen to produce plasmin, the active serine protease that degrades fibrin. The critical pharmacological feature is that tPA preferentially activates plasminogen when it is bound to fibrin — this fibrin-specificity concentrates fibrinolytic activity at the clot surface and limits systemic plasminogen activation. This mechanism underpins the design of all fibrin-specific thrombolytics (alteplase, tenecteplase, reteplase).

Option A: Option A is incorrect: fibrinogen is cleaved to fibrin by thrombin, which is a step in coagulation (clot formation), not fibrinolysis; this is the reverse of what was asked.
Option C: Option C is incorrect: prothrombin-to-thrombin conversion by the prothrombinase complex is a procoagulant reaction in the common pathway of coagulation, not part of the fibrinolytic cascade.
Option D: Option D is incorrect: factor X activation by the intrinsic tenase complex is a step in the intrinsic coagulation pathway, entirely separate from fibrinolysis.
Option E: Option E is incorrect: ADAMTS13 cleaves ultra-large vWF (von Willebrand factor) multimers to prevent pathological platelet aggregation; this is a regulatory mechanism in primary hemostasis, not the fibrinolytic system.

2. A pharmacology student is comparing the mechanisms of alteplase (recombinant tPA) and streptokinase. She wants to understand why alteplase causes less systemic fibrinogen depletion than streptokinase when both agents are used to lyse a coronary thrombus. Which of the following best explains this difference?

A) Alteplase has a longer half-life than streptokinase, allowing it to maintain higher plasma concentrations with a smaller total dose
B) Streptokinase is cleared by the kidneys, while alteplase is cleared by the liver, so streptokinase accumulates in patients with renal impairment
C) Alteplase requires co-administration of heparin to work, whereas streptokinase acts independently, so the systemic effects of streptokinase are amplified by the absence of anticoagulant regulation
D) Alteplase preferentially activates plasminogen that is bound to fibrin at the clot surface, concentrating fibrinolytic activity locally, whereas streptokinase forms an activator complex with free circulating plasminogen, generating systemic plasmin that degrades fibrinogen throughout the circulation
E) Streptokinase is a direct plasmin mimetic that directly cleaves fibrinogen without requiring plasminogen activation, making its fibrinogenolytic effect faster and less selective

ANSWER: D

Rationale:

Option D is correct. The key pharmacological distinction between alteplase and streptokinase is fibrin-specificity. Alteplase (tPA) binds preferentially to fibrin-bound plasminogen at the clot surface, activating it locally; plasmin generated in the circulation is rapidly inactivated by alpha-2-antiplasmin. Streptokinase, by contrast, is a bacterial protein (not an enzyme itself) that forms a stoichiometric 1:1 activator complex with free circulating plasminogen, converting it to plasmin systemically. This systemic plasmin degrades not only fibrin in clots but also circulating fibrinogen, factor V, and factor VIII, producing a systemic lytic state with greater fibrinogen depletion and bleeding risk.

Option A: Option A is incorrect: alteplase has a shorter half-life (approximately 4 to 6 minutes) than streptokinase (approximately 23 minutes for the complex), not a longer one.
Option B: Option B is incorrect: alteplase is cleared by the liver (hepatic clearance), which is accurate, but streptokinase is also cleared via the reticuloendothelial system — this is not the mechanism of fibrin-specificity differences.
Option C: Option C is incorrect: both agents require adjunctive anticoagulation (heparin) in most protocols; co-administration of heparin is not what confers fibrin-specificity to alteplase.
Option E: Option E is incorrect: streptokinase does not directly cleave fibrinogen — it works by activating plasminogen through complex formation; describing it as a direct plasmin mimetic is mechanistically wrong.

3. A 58-year-old man presents to the emergency department with an acute anterior STEMI (ST-segment elevation myocardial infarction, where ST refers to the electrocardiographic ST-segment) and primary PCI (percutaneous coronary intervention) cannot be performed within 120 minutes. The decision is made to administer alteplase. Which of the following correctly describes the pharmacological mechanism by which alteplase lyses the coronary thrombus?

A) Alteplase is a recombinant form of human tissue plasminogen activator (tPA) that binds to fibrin within the thrombus and, while bound, activates fibrin-associated plasminogen to plasmin, which then degrades the fibrin network
B) Alteplase is a monoclonal antibody that binds to the platelet glycoprotein IIb/IIIa receptor, preventing fibrinogen crosslinking and causing thrombus dissolution
C) Alteplase activates the intrinsic coagulation pathway in reverse by inhibiting factor XIIa, thereby dissolving clot from the inside out through contact-activation reversal
D) Alteplase directly cleaves fibrinogen in the circulation, preventing further fibrin polymerization and allowing existing thrombus to dissolve through natural mechanical disruption
E) Alteplase is a vitamin K antagonist that depletes factors II, VII, IX, and X, shifting the coagulation-fibrinolysis balance toward net clot dissolution

ANSWER: A

Rationale:

Option A is correct. Alteplase (rt-PA, recombinant tissue plasminogen activator) is a serine protease that shares the structure of endogenous human tPA. Its critical pharmacological feature is fibrin-binding: alteplase contains a fibronectin finger domain and a kringle-2 domain that together confer high-affinity binding to fibrin within the thrombus. Once bound, alteplase undergoes a conformational change that dramatically increases its catalytic efficiency for cleaving plasminogen to plasmin. The plasmin generated at the clot surface then degrades the fibrin network, dissolving the thrombus.

Option B: Option B is incorrect: glycoprotein IIb/IIIa inhibitors (such as abciximab, eptifibatide, tirofiban) are antiplatelet agents that prevent platelet aggregation but do not lyse existing thrombus; they have no fibrinolytic activity.
Option C: Option C is incorrect: there is no pharmacological mechanism by which any approved thrombolytic works through inhibition of factor XIIa or reversal of the intrinsic pathway; this is fabricated.
Option D: Option D is incorrect: directly cleaving circulating fibrinogen is the mechanism of non-fibrin-specific agents such as streptokinase (via systemic plasmin generation) — alteplase preferentially activates fibrin-bound plasminogen rather than cleaving fibrinogen directly.
Option E: Option E is incorrect: vitamin K antagonists (such as warfarin) inhibit synthesis of vitamin K-dependent clotting factors; they prevent new thrombus formation but do not lyse existing clots and have no thrombolytic action.

4. A 72-year-old woman in a resource-limited hospital setting is treated with streptokinase for acute STEMI (ST-segment elevation myocardial infarction). She recovers uneventfully. Eight months later she presents to the same hospital with a second STEMI. Which of the following properties of streptokinase is most relevant to the clinical decision about whether to use it again?

A) Streptokinase is renally cleared and must be dose-adjusted in patients with reduced creatinine clearance, making repeat dosing unpredictable without a new renal function assessment
B) Streptokinase has a very short half-life of approximately 2 minutes, meaning a repeat dose would be eliminated before it could achieve therapeutic thrombolysis
C) Streptokinase is a bacterial protein derived from streptococcal organisms and is antigenic — prior administration induces neutralizing antibodies that persist for at least 6 to 12 months, rendering repeat dosing ineffective and potentially causing hypersensitivity reactions
D) Streptokinase causes permanent depletion of plasminogen in the circulation after a single administration, making it ineffective for repeat use until plasminogen stores are restored over several years
E) Streptokinase undergoes hepatic first-pass metabolism and induces its own metabolizing enzymes after the first dose, reducing systemic exposure with repeat administration through autoinduction

ANSWER: C

Rationale:

Option C is correct. Streptokinase is a non-human protein of bacterial (streptococcal) origin, and prior exposure — either through infection or prior drug administration — triggers the formation of anti-streptokinase neutralizing antibodies. These antibodies persist in circulation for at least 6 to 12 months and at high titers can neutralize a standard therapeutic dose of streptokinase entirely, rendering it ineffective. Additionally, re-exposure can precipitate allergic reactions ranging from fever and rash to frank anaphylaxis. For this reason, streptokinase is contraindicated within 6 to 12 months of prior administration and is also relatively contraindicated in patients with recent streptococcal infection. A fibrin-specific agent such as alteplase or tenecteplase should be used for this patient's second event.

Option A: Option A is incorrect: streptokinase clearance is primarily through the reticuloendothelial system via breakdown of the streptokinase-plasminogen complex, not renal elimination; dose adjustment for renal function is not a primary concern.
Option B: Option B is incorrect: the streptokinase-plasminogen activator complex has a half-life of approximately 23 minutes, not 2 minutes; a short half-life is not the reason repeat dosing is contraindicated.
Option D: Option D is incorrect: plasminogen depletion after streptokinase is transient and recovers within hours to days; prolonged multi-year depletion does not occur.
Option E: Option E is incorrect: streptokinase does not undergo hepatic first-pass metabolism and does not induce metabolizing enzymes; autoinduction is not a relevant pharmacokinetic property of this drug.

5. A cardiologist is selecting a fibrinolytic agent for a 65-year-old man with acute STEMI (ST-segment elevation myocardial infarction) who is being treated at a community hospital where primary PCI (percutaneous coronary intervention) is not immediately available. The cardiologist notes that platelet-rich thrombi contain high concentrations of PAI-1 (plasminogen activator inhibitor-1, the primary endogenous inhibitor of tPA). Which thrombolytic agent is best suited for this clinical scenario based on its dosing convenience and its resistance to PAI-1 inhibition?

A) Streptokinase, because its mechanism does not involve direct tPA activity and therefore it is intrinsically insensitive to PAI-1 inhibition at any concentration
B) Reteplase, because its double-bolus regimen has been specifically designed to overcome PAI-1 resistance by saturating the inhibitor with sequential dosing
C) Alteplase, because its 90-minute weight-based infusion protocol allows dose titration in response to PAI-1 levels measured during administration
D) Urokinase, because it is the only thrombolytic approved for intracoronary use in STEMI and achieves local drug concentrations sufficient to overcome PAI-1 inhibition
E) Tenecteplase, because it is administered as a single weight-based IV bolus and its T103N/N117Q mutations confer the highest PAI-1 resistance of any approved fibrinolytic agent, making it particularly effective against PAI-1-rich platelet thrombi

ANSWER: E

Rationale:

Option E is correct. Tenecteplase is a bioengineered variant of alteplase with three amino acid substitutions: T103N and N117Q (in the kringle-1 domain) increase its plasma half-life to approximately 20 to 24 minutes (compared with 4 to 6 minutes for alteplase) by reducing hepatic clearance, and the KHRR (296–299) AAAA substitution in the protease domain confers 14-fold greater resistance to inhibition by PAI-1 compared with native tPA. This PAI-1 resistance is clinically important because platelet activation at the site of arterial thrombosis releases large amounts of PAI-1 from alpha-granules. Its single weight-based IV bolus administration (30 to 50 mg based on body weight) is particularly practical in prehospital or community hospital settings.

Option A: Option A is incorrect: while streptokinase is indeed insensitive to PAI-1 because it activates free circulating plasminogen rather than through direct tPA activity, it is not the best choice here — it is antigenic, has a high systemic bleeding risk, and is not selected based on PAI-1 resistance optimization.
Option B: Option B is incorrect: reteplase's double-bolus regimen (two 10-unit IV boluses 30 minutes apart) was designed for dosing convenience, not specifically to overcome PAI-1 resistance; reteplase does not have engineered PAI-1 resistance.
Option C: Option C is incorrect: alteplase's infusion protocol cannot be titrated to PAI-1 levels in real time, and alteplase has substantially less PAI-1 resistance than tenecteplase.
Option D: Option D is incorrect: urokinase is not approved for coronary thrombolysis in STEMI in current practice; its primary use is in catheter-directed thrombolysis for peripheral arterial or venous occlusions.

6. A 67-year-old woman arrives in the emergency department with sudden-onset left-sided weakness and aphasia. Non-contrast CT (computed tomography) scan of the brain shows no hemorrhage and no established large infarct. Her last known well time was 3 hours and 45 minutes ago. Her blood pressure is 178/96 mmHg and blood glucose is 112 mg/dL. Which of the following correctly identifies the maximum time window within which IV alteplase (intravenous alteplase) may be administered for acute ischemic stroke, and the landmark trial that established the extended window?

A) 3 hours from symptom onset, established by the GISSI-1 (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico) trial, which first demonstrated benefit of fibrinolysis in ischemic cerebrovascular events
B) 4.5 hours from symptom onset or last known well time, with the 3 to 4.5 hour window established by the ECASS-3 (European Cooperative Acute Stroke Study 3) trial, which showed improved functional outcomes with alteplase versus placebo in the extended window
C) 6 hours from symptom onset, established by the IST-3 (International Stroke Trial 3), which used perfusion imaging to identify salvageable penumbral tissue up to 6 hours from onset
D) 8 hours from symptom onset for patients with a favorable CT perfusion mismatch ratio, established by the EXTEND-IA (Extending the Time for Thrombolysis in Stroke) trial
E) 24 hours from onset in patients with wake-up stroke, established by the WAKE-UP trial using DWI-FLAIR (diffusion-weighted imaging–fluid-attenuated inversion recovery) mismatch on MRI (magnetic resonance imaging) to identify recent infarction

ANSWER: B

Rationale:

Option B is correct. The approved time window for IV alteplase in acute ischemic stroke is 4.5 hours from symptom onset or last known well time. The original 0 to 3 hour window was established by the NINDS (National Institute of Neurological Disorders and Stroke) tPA stroke trial. The extension to 4.5 hours was supported by the ECASS-3 trial (Hacke et al., NEJM 2008), which randomized 821 patients and demonstrated significantly improved functional outcome (modified Rankin Scale score 0 to 1 at 90 days) with alteplase versus placebo in the 3 to 4.5 hour window. This patient is within the 4.5-hour window; her blood pressure must be lowered to below 185/110 mmHg before alteplase can be administered.

Option A: Option A is incorrect: GISSI-1 was a landmark STEMI (myocardial infarction) trial that established streptokinase for coronary thrombolysis — it had nothing to do with ischemic stroke. The initial approved stroke window of 3 hours was established by the NINDS tPA trial, not GISSI-1.
Option C: Option C is incorrect: the IST-3 trial tested alteplase up to 6 hours in a broad population and found a non-significant trend toward benefit but did not establish a 6-hour approved window; current FDA-approved use remains within 4.5 hours.
Option D: Option D is incorrect: EXTEND-IA examined endovascular thrombectomy following tPA, not an extended tPA window based on perfusion imaging alone; the study does not define an 8-hour alteplase window.
Option E: Option E is incorrect: the WAKE-UP trial demonstrated benefit of MRI-guided alteplase in patients with unknown onset (wake-up stroke) using DWI-FLAIR mismatch, but this represents an imaging-guided selection paradigm for a specific subgroup — it does not define a standard 24-hour alteplase window for all patients.

7. A 55-year-old man (weight 80 kg) with acute ischemic stroke is determined to be an appropriate candidate for IV alteplase. Which of the following correctly describes the standard alteplase dosing regimen for acute ischemic stroke?

A) 1.5 million units IV over 60 minutes as a fixed non-weight-based infusion, identical to the STEMI dosing protocol
B) 100 mg IV over 2 hours as a fixed dose regardless of body weight, the same regimen used for pulmonary embolism
C) 0.6 mg/kg IV over 15 minutes as a rapid infusion with a maximum dose of 50 mg, used when cardiac arrest complicates the presentation
D) 0.9 mg/kg IV, with 10% of the total dose given as an IV bolus over 1 minute and the remaining 90% infused over 60 minutes, with a maximum total dose of 90 mg
E) 30 to 50 mg IV as a single weight-based bolus, given over 5 to 10 seconds, with the exact dose determined by the patient's body weight in 10-kg increments

ANSWER: D

Rationale:

Option D is correct. The standard IV alteplase dose for acute ischemic stroke is 0.9 mg/kg, with a maximum total dose of 90 mg regardless of body weight. The administration protocol divides the dose: 10% of the total calculated dose is given as an immediate IV bolus over 1 minute, and the remaining 90% is infused over 60 minutes. For this 80 kg patient: total dose = 0.9 × 80 = 72 mg; bolus = 7.2 mg over 1 minute; infusion = 64.8 mg over 60 minutes. This weight-based approach differs from the fixed-dose regimens used in STEMI and PE.

Option A: Option A is incorrect: 1.5 million units over 60 minutes is the streptokinase dose for STEMI — alteplase is dosed in milligrams, not units, and uses a weight-based rather than fixed regimen.
Option B: Option B is incorrect: alteplase 100 mg over 2 hours is the standard regimen for massive PE (pulmonary embolism), not for ischemic stroke; the stroke dose is both lower in total amount (maximum 90 mg) and uses a weight-based calculation.
Option C: Option C is incorrect: the 0.6 mg/kg rapid infusion with a maximum of 50 mg over 15 minutes is a modified alteplase protocol used in the setting of cardiac arrest, not the standard stroke protocol.
Option E: Option E is incorrect: the single weight-based IV bolus administered in seconds describes the tenecteplase dosing protocol for STEMI — not the alteplase stroke protocol, which requires a bolus-plus-infusion administration.

8. Before administering alteplase for acute ischemic stroke, the treating physician is reviewing the patient's history for contraindications. Which of the following represents an absolute contraindication that applies regardless of the size of the neurological deficit or the potential clinical benefit of thrombolysis?

A) Age above 80 years, which is an absolute contraindication for alteplase in the 0 to 3 hour window because of increased intracranial hemorrhage risk in elderly patients
B) A history of minor ischemic stroke with complete recovery 6 months ago, which permanently disqualifies the patient from future alteplase administration
C) A history of prior intracranial hemorrhage (intracerebral hemorrhage or subarachnoid hemorrhage) at any time in the past, which represents an absolute contraindication to alteplase for all indications including stroke, STEMI, and pulmonary embolism
D) Active anticoagulant therapy with therapeutic anticoagulation, which is an absolute contraindication regardless of the INR (international normalized ratio) value or time since the last dose
E) A seizure at the time of stroke onset, which is an absolute contraindication because it indicates hemorrhagic transformation has already occurred

ANSWER: C

Rationale:

Option C is correct. A history of prior intracranial hemorrhage (ICH) — whether intracerebral hemorrhage or subarachnoid hemorrhage — at any time in the past is an absolute contraindication to alteplase and to thrombolytic therapy in all indications including stroke, STEMI, and PE. The rationale is that prior ICH indicates a brain vasculature with established vulnerability to hemorrhage, and the plasmin-mediated fibrinolysis produced by alteplase dramatically increases the risk of recurrent intracranial bleeding in such patients. This contraindication does not have a time cutoff — it is permanent.

Option A: Option A is incorrect: age above 80 years is not an absolute contraindication in the 0 to 3 hour window; guidelines permit alteplase use in patients over 80 within the first 3 hours. It is a restriction (not an absolute contraindication) for the 3 to 4.5 hour extended window per ECASS-3 exclusion criteria.
Option B: Option B is incorrect: a prior ischemic stroke does not permanently disqualify a patient from alteplase — ischemic stroke within the preceding 3 months is a contraindication, but a stroke 6 months ago with complete recovery does not constitute an absolute contraindication to future treatment.
Option D: Option D is incorrect: therapeutic anticoagulation with INR above 1.7 is an absolute contraindication for stroke thrombolysis, but this criterion is INR-dependent; an anticoagulated patient with an INR within acceptable range is not automatically excluded. For DOACs (direct oral anticoagulants), the dose and timing of the last dose determine eligibility.
Option E: Option E is incorrect: a seizure at stroke onset is a relative contraindication (not absolute) in current guidelines, provided that neuroimaging confirms ischemia rather than a postictal state or hemorrhage.

9. A 68-year-old man undergoes coronary artery bypass surgery on cardiopulmonary bypass (CPB). He received 30,000 units of UFH (unfractionated heparin) at the start of CPB approximately 2.5 hours ago. The surgeon requests reversal of heparin anticoagulation at the conclusion of the procedure. Which of the following correctly describes the mechanism and dosing of the appropriate reversal agent?

A) Protamine sulfate, a highly positively charged protein, forms a stable ionic complex with the polyanionic heparin molecule, rendering it pharmacologically inactive; the dose is 1 mg protamine per 100 units of UFH administered in the preceding 2 to 3 hours, giving approximately 300 mg in this case
B) Andexanet alfa, a recombinant decoy factor Xa molecule, binds and sequesters circulating heparin-antithrombin complexes, restoring factor Xa activity; the dose is 400 mg IV bolus followed by 480 mg IV over 2 hours
C) Idarucizumab, a monoclonal antibody fragment that binds heparin with high affinity, neutralizing its anticoagulant activity regardless of the heparin dose administered; given as 5 g IV in two 2.5 g boluses
D) Vitamin K1 (phytonadione), which competes with heparin for binding to antithrombin III and displaces it, restoring thrombin and factor Xa activity; given as 10 mg IV over 30 minutes
E) Fresh frozen plasma (FFP), which contains supraphysiological concentrations of antithrombin III that overwhelm heparin binding capacity and restore hemostasis; given as 4 units IV over 30 minutes

ANSWER: A

Rationale:

Option A is correct. Protamine sulfate is the specific reversal agent for UFH. Protamine is a strongly basic (positively charged) protein originally derived from salmon sperm nuclei; heparin is a strongly acidic (negatively charged) polysaccharide. The two molecules form a stable ionic complex that is pharmacologically inert and is cleared by the reticuloendothelial system. The standard dosing formula is 1 mg protamine per 100 units of UFH administered in the preceding 2 to 3 hours (only the heparin remaining active is counted, as heparin has a half-life of approximately 1 to 2 hours). For 30,000 units given approximately 2.5 hours ago, approximately 300 mg protamine is appropriate (accounting for partial heparin clearance). The IV rate should not exceed 5 mg/min (maximum 50 mg over 10 minutes) to reduce adverse effects.

Option B: Option B is incorrect: andexanet alfa is a specific reversal agent for factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) — it has no activity against heparin and is not used for UFH reversal.
Option C: Option C is incorrect: idarucizumab is a monoclonal antibody fragment specific for dabigatran (a direct thrombin inhibitor); it has no binding affinity for heparin and cannot reverse its anticoagulant effects.
Option D: Option D is incorrect: vitamin K1 reverses warfarin anticoagulation by restoring vitamin K-dependent factor synthesis; it has no mechanism of action relevant to heparin, which works through antithrombin potentiation and does not involve vitamin K-dependent factors.
Option E: Option E is incorrect: FFP contains clotting factors (and antithrombin) at normal plasma concentrations, but administering antithrombin would potentiate heparin's activity, not reverse it; FFP is not a heparin reversal strategy.

10. A 74-year-old woman on long-term warfarin presents with an INR (international normalized ratio) of 8.2 and minor gum bleeding. She has no signs of serious bleeding and no acute surgical need. The decision is made to administer oral vitamin K. Her physician explains that INR correction will take 24 to 48 hours. Which of the following best explains why vitamin K cannot rapidly reverse warfarin anticoagulation even when given in adequate doses?

A) Vitamin K must first be converted to its active form by intestinal bacteria through a multi-step fermentation process before it can enter the portal circulation, introducing a delay of 24 to 36 hours regardless of route
B) Vitamin K competes with warfarin for binding to VKOR (vitamin K epoxide reductase) and must reach a molar excess sufficient to displace warfarin from the enzyme, which takes 24 to 48 hours to achieve at standard oral doses
C) Vitamin K is sequestered by albumin in the portal circulation after oral absorption, and the time required for hepatic albumin dissociation and intracellular uptake determines the rate of anticoagulation reversal
D) Warfarin must be fully metabolized and eliminated before vitamin K can exert its effect, and warfarin's half-life of approximately 36 to 42 hours means that the drug remains active for at least 24 hours after the last dose regardless of vitamin K administration
E) Vitamin K restores the activity of VKOR (vitamin K epoxide reductase), enabling synthesis of the reduced vitamin K needed for gamma-carboxylation of new clotting factor proteins; however, reversing anticoagulation requires waiting for new factor molecules to be synthesized and secreted by the liver, and factor half-lives range from approximately 4 to 6 hours for factor VII to approximately 60 to 72 hours for prothrombin (factor II)

ANSWER: E

Rationale:

Option E is correct. Warfarin inhibits VKOR (vitamin K epoxide reductase), the enzyme that recycles vitamin K epoxide back to the reduced hydroquinone form (vitamin KH2) needed for gamma-carboxylation of glutamic acid residues on clotting factors II, VII, IX, and X. Exogenous vitamin K (phytonadione) bypasses VKOR by being directly reduced to KH2 by an alternate, warfarin-insensitive reductase (DT-diaphorase), restoring substrate for gamma-carboxylation. However, the INR can only normalize as new, fully carboxylated clotting factors are synthesized, secreted, and accumulate to functional concentrations. Factor VII has the shortest half-life (approximately 4 to 6 hours) and recovers first, producing measurable INR improvement within 6 to 8 hours after IV vitamin K and 24 to 48 hours after oral vitamin K. Prothrombin (factor II, half-life approximately 60 to 72 hours) is the last to recover. The rate of reversal is thus limited by factor synthesis kinetics, not vitamin K pharmacokinetics.

Option A: Option A is incorrect: vitamin K does not require bacterial conversion — phytonadione (vitamin K1) is a preformed fat-soluble vitamin absorbed from the gut; oral bioavailability after absorption is sufficient for anticoagulation reversal and does not require intestinal bacterial processing.
Option B: Option B is incorrect: vitamin K does not compete with warfarin for VKOR binding — it bypasses VKOR entirely through an alternate reductase; the delay is not due to competitive displacement kinetics.
Option C: Option C is incorrect: albumin sequestration in the portal circulation is not a pharmacokinetically significant rate-limiting step for vitamin K; while vitamin K is lipophilic and does associate with lipoproteins, hepatic uptake is not rate-limited by albumin dissociation in the manner described.
Option D: Option D is incorrect: while warfarin's half-life (approximately 36 to 42 hours) does contribute to the sustained anticoagulant effect, vitamin K administration can restore factor synthesis even while warfarin remains in the circulation; the reversal delay is primarily explained by clotting factor synthesis kinetics, not warfarin elimination.

11. A 79-year-old man with atrial fibrillation on dabigatran (a DTI — direct thrombin inhibitor) presents with a large intracranial hemorrhage requiring emergency neurosurgical evacuation. The neurosurgeon requests immediate reversal of anticoagulation before proceeding to the operating room. Which of the following is the correct reversal agent and its mechanism of action?

A) Andexanet alfa, which acts as a decoy factor Xa receptor and sequesters dabigatran molecules away from thrombin, restoring clot formation at the surgical site
B) Idarucizumab, a humanized monoclonal antibody fragment (Fab) that binds dabigatran with approximately 350-fold higher affinity than dabigatran has for thrombin, forming an irreversible 1:1 complex that immediately neutralizes dabigatran's anticoagulant effect
C) Protamine sulfate, which forms an ionic complex with dabigatran in the same manner it neutralizes heparin, because dabigatran shares a similar polyanionic charge distribution
D) Four-factor PCC (prothrombin complex concentrate), which provides an overwhelming excess of thrombin substrate (factors II, VII, IX, X), effectively bypassing dabigatran's thrombin inhibition by saturating the drug with competing substrates
E) Vitamin K administered intravenously at 10 mg, which reverses dabigatran anticoagulation within 6 to 8 hours by restoring thrombin activity through the vitamin K-dependent coagulation factor synthesis pathway

ANSWER: B

Rationale:

Option B is correct. Idarucizumab (Praxbind) is a humanized monoclonal antibody Fab fragment engineered specifically to reverse dabigatran. It binds dabigatran with an affinity approximately 350 times greater than dabigatran's binding affinity for thrombin, capturing both free and thrombin-bound dabigatran in the circulation. The resulting complex is pharmacologically inert and is renally excreted. The approved dose is 5 g IV as two consecutive 2.5 g boluses given no more than 15 minutes apart. In the RE-VERSE AD trial, idarucizumab produced immediate and complete reversal of dabigatran anticoagulation (median maximum reversal 100%) in patients with serious bleeding or requiring urgent surgery.

Option A: Option A is incorrect: andexanet alfa is specific for factor Xa inhibitors (apixaban, rivaroxaban, edoxaban, betrixaban) — it acts as a decoy factor Xa molecule, not a thrombin-binding agent; it has no activity against dabigatran, which is a direct thrombin inhibitor, not a factor Xa inhibitor.
Option C: Option C is incorrect: protamine sulfate reverses UFH and partially reverses LMWH through ionic interactions with the negatively charged heparin polysaccharide; dabigatran is a small synthetic molecule that does not share heparin's polyanionic charge structure, and protamine has no meaningful activity against dabigatran.
Option D: Option D is incorrect: while 4F-PCC (four-factor prothrombin complex concentrate) can be used as a non-specific alternative when idarucizumab is unavailable, it does not neutralize dabigatran through thrombin substrate saturation; providing excess prothrombin does not compete with dabigatran's inhibition of active thrombin.
Option E: Option E is incorrect: vitamin K reverses warfarin (VKA) anticoagulation through restoration of vitamin K-dependent factor synthesis; dabigatran is a direct thrombin inhibitor that is completely independent of the vitamin K pathway; vitamin K has absolutely no effect on dabigatran anticoagulation.

12. A 71-year-old woman on apixaban (a direct factor Xa inhibitor) for atrial fibrillation presents with a large GI (gastrointestinal) hemorrhage unresponsive to endoscopic hemostasis. Andexanet alfa is available. Which of the following correctly describes andexanet alfa's mechanism of action and why the catalytic serine residue of its factor Xa scaffold was deliberately mutated?

A) Andexanet alfa is a monoclonal antibody that binds apixaban in the bloodstream and transports it to the kidney for accelerated urinary excretion, reducing plasma drug concentration; the catalytic serine was mutated to prevent the antibody from activating complement
B) Andexanet alfa is a recombinant factor Xa molecule that competes with native factor Xa for apixaban binding at the active site; the catalytic serine was mutated to reduce its procoagulant potency so it does not generate excess thrombin while bound to apixaban
C) Andexanet alfa is a modified recombinant inactive form of human factor Xa that acts as a decoy receptor — it binds and sequesters factor Xa inhibitors (including apixaban) in the circulation by mimicking factor Xa's active site; the catalytic serine was mutated to eliminate enzymatic activity so that andexanet does not generate thrombin while sequestering the inhibitor
D) Andexanet alfa is a competitive inhibitor of the factor Xa–apixaban complex that displaces apixaban from factor Xa by exploiting higher binding affinity; the catalytic serine was mutated to increase binding affinity for apixaban beyond that achievable with native factor Xa
E) Andexanet alfa replaces the factor Xa molecules that have been inhibited by apixaban by occupying prothrombin binding sites on the prothrombinase complex, restoring thrombin generation; the catalytic serine mutation was required to prevent andexanet from being incorporated into the complex as a functional enzyme

ANSWER: C

Rationale:

Option C is correct. Andexanet alfa (Andexxa) is an engineered, catalytically inactive recombinant human factor Xa that serves as a decoy receptor for factor Xa inhibitors. Because it retains the structural binding site for factor Xa inhibitors (including apixaban, rivaroxaban, edoxaban, and betrixaban) but lacks enzymatic activity, it sequesters the inhibitor drug in the circulation — reducing free drug concentration and allowing native factor Xa to function. The critical engineering feature is the serine-to-alanine substitution at the catalytic site (S419A): without this mutation, the recombinant factor Xa would generate thrombin and cause pathological procoagulant effects. ANNEXA-4 (n = 352) demonstrated good or excellent hemostasis in 82% of patients at 12 hours.

Option A: Option A is incorrect: andexanet alfa is not a monoclonal antibody and does not promote renal drug excretion; it acts by sequestering the drug in the circulation, not by removing it from the body.
Option B: Option B is incorrect: describing the mechanism as "competition with native factor Xa for apixaban binding" confuses the pharmacology — andexanet does not compete with factor Xa for apixaban; rather, it itself acts as a structural mimic of factor Xa to capture the inhibitor. The rationale for the serine mutation is not reduced procoagulant potency in the bound state but prevention of catalytic thrombin generation by andexanet itself.
Option D: Option D is incorrect: andexanet alfa does not displace apixaban from native factor Xa through competitive binding; it captures free apixaban in the circulation through its decoy mechanism, reducing the free drug available to inhibit native factor Xa.
Option E: Option E is incorrect: andexanet alfa does not occupy prothrombin binding sites on the prothrombinase complex; it circulates freely as a decoy and does not insert into the coagulation cascade assembly.

13. A 66-year-old man on warfarin (a VKA — vitamin K antagonist) for mechanical heart valve presents with acute onset left hemiplegia. Brain CT (computed tomography) scan shows a large right-hemisphere hemorrhagic stroke. His INR (international normalized ratio) is 4.8. Neurosurgery requests emergent reversal of anticoagulation. Which of the following is the most appropriate immediate management?

A) Administer IV vitamin K 10 mg alone and recheck the INR in 6 to 8 hours before proceeding to surgery, as this approach achieves complete reversal without the thrombotic risks associated with prothrombin complex concentrates
B) Administer fresh frozen plasma (FFP) 4 units IV immediately, as FFP contains all clotting factors and achieves more complete and rapid INR correction than prothrombin complex concentrate in the setting of acute intracranial hemorrhage
C) Administer idarucizumab 5 g IV as warfarin, like dabigatran, directly inhibits thrombin, and idarucizumab's high-affinity thrombin-binding action will neutralize the warfarin-induced coagulopathy within minutes
D) Administer four-factor PCC (prothrombin complex concentrate, also called 4F-PCC or Kcentra) dosed by weight and INR (35 units/kg for INR 4 to 6, maximum 3,500 units) alongside IV vitamin K 10 mg simultaneously, achieving rapid INR correction within 15 to 30 minutes from PCC and sustained reversal from vitamin K
E) Administer andexanet alfa (low-dose regimen: 400 mg IV bolus followed by 480 mg over 2 hours) because warfarin inhibits the synthesis of factor Xa along with other coagulation factors, and andexanet's decoy factor Xa mechanism restores the net coagulation balance

ANSWER: D

Rationale:

Option D is correct. For urgent or emergent reversal of VKA (vitamin K antagonist) anticoagulation with life-threatening bleeding, the preferred strategy is 4F-PCC (four-factor prothrombin complex concentrate) combined with IV vitamin K. 4F-PCC contains concentrated factors II, VII, IX, and X as well as proteins C and S, and achieves INR correction within 15 to 30 minutes regardless of the starting INR. This patient has INR 4 to 6, so 35 units/kg (maximum 3,500 units) is the appropriate PCC dose. IV vitamin K 10 mg must be given simultaneously: without it, as PCC is cleared (factor half-lives 6 to 24 hours), the INR will rebound as warfarin's effect persists and new factor synthesis remains suppressed. The combination provides both immediate factor replacement (PCC) and sustained reversal (vitamin K).

Option A: Option A is incorrect: IV vitamin K alone, even in adequate doses, requires 6 to 12 hours for measurable INR reduction because it depends on synthesis of new factor proteins; in emergent intracranial hemorrhage, this delay is unacceptable — PCC is required for immediate reversal.
Option B: Option B is incorrect: FFP does contain all clotting factors but at normal plasma concentrations, requiring large volumes (15 to 20 mL/kg, or approximately 4 to 6 units) to correct severe coagulopathy and taking 30 minutes of thawing time before administration; 4F-PCC corrects INR faster, in smaller volumes, and without the risk of fluid overload or TRALI (transfusion-related acute lung injury); FFP is inferior to 4F-PCC for urgent VKA reversal.
Option C: Option C is incorrect: idarucizumab is a specific reversal agent for dabigatran (a direct thrombin inhibitor); warfarin acts through inhibition of vitamin K-dependent factor synthesis — a completely different mechanism from direct thrombin inhibition — and idarucizumab has no activity against warfarin's coagulopathy.
Option E: Option E is incorrect: andexanet alfa is specific for direct factor Xa inhibitors (apixaban, rivaroxaban, edoxaban); warfarin does not directly inhibit factor Xa — it depletes all four vitamin K-dependent factors (II, VII, IX, X) through VKOR inhibition, and andexanet has no reversal activity for warfarin anticoagulation.

14. A 61-year-old man received IV alteplase 45 minutes ago for acute ischemic stroke. He now develops acute neurological deterioration. Emergent non-contrast CT confirms symptomatic intracranial hemorrhage (sICH). The alteplase infusion is immediately stopped. Laboratory results show fibrinogen 88 mg/dL (reference range 200 to 400 mg/dL), platelet count 210,000/mcL, INR 1.1, and aPTT (activated partial thromboplastin time) 32 seconds. Which blood product is the most appropriate next step for rapid fibrinogen replacement in this setting?

A) Cryoprecipitate (10 units IV), because each unit contains approximately 150 to 250 mg of fibrinogen in a concentrated volume and raises circulating fibrinogen by approximately 5 to 7 mg/dL per unit in an average adult, making it the volume-efficient choice for targeted fibrinogen replacement after thrombolytic bleeding
B) Fresh frozen plasma (4 to 6 units IV), because FFP contains the highest concentration of fibrinogen per unit volume of any available blood product and is the most reliable way to achieve rapid fibrinogen normalization after thrombolytic administration
C) Platelet transfusion (1 apheresis unit), because the primary hemostatic defect after alteplase is fibrin-poor platelet plug formation due to plasmin-mediated platelet surface protein degradation, and restoring platelet mass is more important than restoring fibrinogen
D) Prothrombin complex concentrate (4F-PCC, 25 units/kg IV), because the fibrinogen depletion is caused by vitamin K-dependent factor consumption and 4F-PCC provides simultaneous replacement of factors II, VII, IX, and X alongside fibrinogen
E) Recombinant factor VIIa (rFVIIa, 90 mcg/kg IV), because thrombolytic-induced fibrinogen depletion is best reversed by providing an exogenous source of factor VIIa that bypasses the fibrin network requirement and directly activates thrombin at the platelet surface

ANSWER: A

Rationale:

Option A is correct. Cryoprecipitate is the preferred product for rapid fibrinogen replacement in thrombolytic-associated bleeding. Each unit of cryoprecipitate is prepared by thawing FFP at cold temperatures and collecting the precipitated proteins, which include fibrinogen (approximately 150 to 250 mg per unit), factor VIII, factor XIII, vWF (von Willebrand factor), and fibronectin — all in a small volume (approximately 15 to 30 mL per unit). A standard empirical dose of 10 units raises fibrinogen by approximately 50 to 70 mg/dL in an average adult, which should bring this patient's fibrinogen from 88 mg/dL toward the target of above 150 mg/dL. The fibrinogen level should be rechecked after the first dose and repeated until the target is met. Antifibrinolytic therapy (tranexamic acid or aminocaproic acid) should be given simultaneously to inhibit ongoing plasmin-mediated fibrinogen and fibrin degradation.

Option B: Option B is incorrect: FFP contains fibrinogen at a much lower concentration (approximately 2 to 3 mg/mL per unit, or approximately 400 to 600 mg per unit volume of 200 to 250 mL) compared with cryoprecipitate (approximately 15 to 30 mg/mL per unit); achieving the same fibrinogen replacement with FFP would require very large volumes (at least 4 to 6 units) with high fluid overload risk — cryoprecipitate is far more volume-efficient for targeted fibrinogen replacement.
Option C: Option C is incorrect: this patient's platelet count is 210,000/mcL, which is well above the threshold for platelet transfusion (below 100,000/mcL with active bleeding); platelet transfusion is not the priority here. Plasmin does degrade some platelet surface glycoproteins, but the primary hemostatic defect is fibrinogen depletion.
Option D: Option D is incorrect: 4F-PCC contains factors II, VII, IX, and X and proteins C and S — it does not contain fibrinogen in meaningful amounts; PCC is used for VKA reversal, not for fibrinogen replacement after thrombolytic bleeding.
Option E: Option E is incorrect: rFVIIa is an off-label rescue measure for refractory hemorrhage unresponsive to cryoprecipitate and antifibrinolytics; it is not the first-line intervention for thrombolytic-induced fibrinogen depletion when the fibrinogen level has been directly measured and confirmed low.

15. A trauma surgeon administers tranexamic acid (TXA) to a 38-year-old man with major hemorrhage following a motor vehicle collision. A medical student asks how TXA stops bleeding at the molecular level. Which of the following correctly describes TXA's mechanism of antifibrinolytic action?

A) TXA is a serine protease inhibitor that binds irreversibly to the active site of plasmin, forming a covalent complex that permanently inactivates circulating plasmin and prevents further fibrin degradation
B) TXA competitively inhibits thrombin's fibrinogen-binding site, preventing fibrinogen cleavage and allowing existing fibrin clots to remain intact without further degradation by the coagulation system
C) TXA activates plasminogen activator inhibitor-1 (PAI-1) by binding to its reactive site loop, increasing endogenous tPA inhibition and reducing circulating tPA concentrations to below the threshold needed for fibrinolysis
D) TXA is a vitamin K analogue that competitively inhibits VKOR (vitamin K epoxide reductase) in endothelial cells lining injured vessels, locally increasing clotting factor synthesis at the site of hemorrhage
E) TXA is a synthetic lysine analogue that competitively inhibits the lysine-binding sites (kringle domains) within plasminogen, blocking plasminogen's ability to bind fibrin and preventing its activation to plasmin by tPA at the clot surface

ANSWER: E

Rationale:

Option E is correct. Tranexamic acid (TXA) is a synthetic analogue of the amino acid lysine. Plasminogen contains multiple kringle domains — structural loops that contain lysine-binding sites (LBS) essential for plasminogen's attachment to lysine residues on fibrin within a clot. By occupying these lysine-binding sites, TXA competitively blocks plasminogen from binding to fibrin. Without fibrin-bound plasminogen, tPA (tissue plasminogen activator) cannot efficiently activate plasminogen to plasmin at the clot surface, because tPA activation efficiency is dramatically enhanced when plasminogen is fibrin-bound. The net effect is inhibition of fibrinolysis, stabilization of existing clots, and reduced bleeding. Epsilon-aminocaproic acid (EACA) shares this same mechanism.

Option A: Option A is incorrect: TXA is not a serine protease inhibitor and does not covalently inactivate plasmin; alpha-2-antiplasmin is the physiological serine protease inhibitor of plasmin. TXA acts at the substrate (fibrin) binding step before plasmin generation, not after.
Option B: Option B is incorrect: TXA has no activity at thrombin's fibrinogen-binding site; thrombin and the coagulation cascade are entirely separate from the fibrinolytic system that TXA targets.
Option C: Option C is incorrect: TXA does not activate PAI-1 and has no known interaction with PAI-1's reactive site loop; this mechanism is fabricated.
Option D: Option D is incorrect: TXA is not a vitamin K analogue and has no activity at VKOR; its antifibrinolytic mechanism is entirely through plasminogen's kringle domain lysine-binding sites.

16. The CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) trial enrolled over 20,000 trauma patients with significant hemorrhage and evaluated tranexamic acid (TXA) administration. Which of the following correctly summarizes the key clinical finding of CRASH-2 and its most important time-dependent caveat?

A) TXA reduced the rate of blood transfusion by 40% regardless of the time from injury to drug administration, with no difference in mortality between early and late treatment groups, establishing a 12-hour therapeutic window for TXA in trauma
B) TXA given within 3 hours of injury reduced all-cause mortality and death due to bleeding, but TXA given more than 3 hours after injury provided no mortality benefit and may have caused harm, establishing a strict 3-hour treatment window
C) TXA reduced mortality only in patients with penetrating trauma (stab wounds, gunshot wounds) but showed no benefit in blunt trauma patients, limiting its indication to penetrating mechanisms only
D) TXA reduced mortality in patients who received it within 1 hour of injury (the platinum window) but showed no benefit beyond 1 hour, making prehospital administration mandatory for clinical benefit
E) TXA eliminated the need for blood transfusion in patients with trauma hemorrhage when given within 6 hours, but increased the rate of venous thromboembolism (VTE) by approximately 25%, offsetting the survival benefit in patients who survived past 30 days

ANSWER: B

Rationale:

Option B is correct. The CRASH-2 trial (Lancet, 2010; n = 20,211) is the pivotal trial establishing TXA's role in trauma hemorrhage. The trial demonstrated that TXA significantly reduced all-cause mortality (14.5% vs. 16.0%, relative risk reduction approximately 9%) and death due to bleeding, with no significant increase in vascular occlusive events (stroke, MI, PE, or DVT). The critical time-dependency finding was that the benefit was confined to patients treated within 3 hours of injury: early treatment (0 to 1 hour) and treatment at 1 to 3 hours both showed benefit, but treatment more than 3 hours after injury was associated with an increased risk of death from bleeding, suggesting that late TXA may paradoxically promote bleeding (possibly by inhibiting late-phase reactive fibrinolysis that aids clot remodeling, or by shifting the balance toward net thrombosis). This 3-hour rule has become a core principle of damage control resuscitation: if TXA cannot be given within 3 hours, it should not be given at all.

Option A: Option A is incorrect: CRASH-2 showed a clear time-dependent effect with potential harm beyond 3 hours — a 12-hour window is not supported; benefit was not maintained regardless of timing.
Option C: Option C is incorrect: CRASH-2 enrolled both blunt and penetrating trauma patients and showed overall mortality benefit across mechanisms; it was not limited to penetrating trauma only.
Option D: Option D is incorrect: while earlier administration is better and prehospital TXA is strongly encouraged by current protocols, CRASH-2 showed benefit for administration up to 3 hours from injury — not exclusively within 1 hour; the data do not restrict benefit to the first hour alone.
Option E: Option E is incorrect: CRASH-2 did not demonstrate a 25% increase in VTE with TXA; the trial found no significant increase in vascular occlusive events, and TXA does not eliminate the need for transfusion — it reduces bleeding and mortality.

17. A 52-year-old woman presents to the emergency department with sudden-onset dyspnea, hypotension (BP 82/50 mmHg for the past 20 minutes), and CT pulmonary angiography confirming massive bilateral PE (pulmonary embolism) with RV (right ventricular) dilation. She has no contraindications to thrombolysis. She is not in cardiac arrest. Which of the following is the most appropriate thrombolytic regimen for this indication?

A) Alteplase 0.9 mg/kg IV (maximum 90 mg) with 10% as a bolus and 90% over 60 minutes — the same weight-based regimen used for acute ischemic stroke, applied here because the weight-based approach minimizes hemorrhagic risk in massive PE
B) Streptokinase 1.5 million units IV over 60 minutes, which is preferred over fibrin-specific agents for massive PE because non-fibrin-specific agents produce more complete clot dissolution in the pulmonary vasculature
C) Tenecteplase in a single weight-based IV bolus (30 to 50 mg based on body weight), which is FDA-approved as the first-line thrombolytic for massive PE because its single-bolus convenience reduces administration errors in the emergency setting
D) Alteplase 100 mg IV over 2 hours as a fixed-dose infusion, which is the standard FDA-approved systemic thrombolytic regimen for massive (high-risk) PE in hemodynamically unstable patients who are not in cardiac arrest
E) Reteplase given as two 10-unit IV boluses 30 minutes apart — the same double-bolus regimen used for STEMI — which is approved for massive PE because its weight-independent dosing simplifies administration in critically ill patients

ANSWER: D

Rationale:

Option D is correct. For massive PE (high-risk PE), defined by hemodynamic instability (systolic BP below 90 mmHg persisting for at least 15 minutes, vasopressor requirement, cardiac arrest, or signs of severe right ventricular failure), systemic IV thrombolysis is the standard of care when there are no absolute contraindications. The FDA-approved regimen for alteplase in PE is 100 mg IV over 2 hours as a fixed-dose infusion (not weight-based). A rapid infusion protocol of 0.6 mg/kg (maximum 50 mg) over 15 minutes is reserved specifically for patients in cardiac arrest. Alteplase is the only thrombolytic with an approved indication for PE in the United States.

Option A: Option A is incorrect: the 0.9 mg/kg weight-based regimen with 10% bolus and 90% over 60 minutes is the alteplase dosing protocol for acute ischemic stroke — not for PE; the PE regimen is a fixed 100 mg over 2 hours.
Option B: Option B is incorrect: while streptokinase does have a historical role in PE (1.5 million units over 60 to 120 minutes), it is not preferred over fibrin-specific agents in current practice due to its antigenicity, systemic lytic state, and higher bleeding risk; and describing non-fibrin-specific agents as superior for pulmonary clot dissolution is not a current guideline-supported rationale.
Option C: Option C is incorrect: tenecteplase is not FDA-approved for PE; it is approved for STEMI only in the United States. The PEITHO trial studied tenecteplase in submassive (intermediate-risk) PE and showed increased bleeding, further discouraging tenecteplase use in this setting.
Option E: Option E is incorrect: reteplase is approved for STEMI only; it is not approved for PE treatment in the United States and has no established role in this indication.

18. A 69-year-old woman with non-valvular atrial fibrillation was treated with IV alteplase for acute ischemic stroke 90 minutes ago and is clinically improving. Her home medication includes apixaban for stroke prevention, which she held for 48 hours before the stroke event. A neurology resident asks when antiplatelet and anticoagulant therapy should be restarted. Which of the following correctly describes the post-thrombolysis antithrombotic management protocol?

A) Aspirin 325 mg should be administered immediately upon completion of the alteplase infusion to prevent early reocclusion of the cerebral vasculature, as the clinical benefit of antiplatelet therapy in the first 24 hours outweighs the hemorrhagic transformation risk
B) Apixaban should be restarted at 24 hours regardless of the stroke size or neuroimaging findings, as the risk of cardioembolic recurrence from atrial fibrillation during any anticoagulation gap exceeds the risk of hemorrhagic transformation
C) All antithrombotic therapy (antiplatelet and anticoagulant) must be withheld for 24 hours after alteplase administration; brain CT or MRI should be performed at 24 hours to exclude hemorrhagic transformation before any antithrombotic agent is resumed; for patients with atrial fibrillation requiring oral anticoagulation, initiation is typically deferred 4 to 14 days depending on infarct size
D) Heparin infusion should be started within 12 hours to bridge to apixaban, as early systemic anticoagulation after stroke thrombolysis reduces the rate of early neurological deterioration by preventing propagation of the ischemic penumbra
E) No antithrombotic therapy is needed for at least 30 days after stroke thrombolysis, as resumed anticoagulation within this period significantly increases the risk of symptomatic hemorrhagic transformation regardless of neuroimaging results

ANSWER: C

Rationale:

Option C is correct. After IV alteplase for acute ischemic stroke, all antithrombotic agents — both antiplatelet and anticoagulant — must be withheld for 24 hours to reduce the risk of hemorrhagic transformation of the ischemic infarct. Brain CT or MRI is performed at 24 hours before resuming any antithrombotic; if imaging shows no hemorrhagic transformation, antiplatelet therapy (aspirin 81 to 325 mg) is typically resumed at 24 hours for most patients with non-cardioembolic stroke. For patients with atrial fibrillation (such as this patient on apixaban), anticoagulation initiation after thrombolysis is deferred beyond 24 hours and the timing depends on infarct size and hemorrhagic transformation risk on imaging: typically 4 to 5 days for small infarcts and up to 14 days for large infarcts or those with hemorrhagic transformation. Blood pressure must be maintained below 180/105 mmHg for at least 24 hours post-thrombolysis.

Option A: Option A is incorrect: antithrombotic agents including aspirin must be held for the full 24 hours after alteplase — administering aspirin immediately after the infusion while the patient remains in a plasmin-mediated lytic state significantly increases hemorrhagic transformation risk.
Option B: Option B is incorrect: restarting apixaban at 24 hours is not appropriate for patients with atrial fibrillation after thrombolysis — the 4 to 14 day deferral is based on infarct size and hemorrhagic risk; while AF does increase cardioembolic recurrence risk, the short-term hemorrhagic transformation risk of early DOAC initiation outweighs this for most patients with significant infarct burden.
Option D: Option D is incorrect: heparin bridging is specifically not recommended in the early post-thrombolysis period; starting any parenteral anticoagulant within 12 to 24 hours significantly increases hemorrhagic transformation risk and is contraindicated in routine post-alteplase stroke management.
Option E: Option E is incorrect: a 30-day blanket restriction on antithrombotic therapy is not guideline-supported; withholding antiplatelet therapy for 30 days after ischemic stroke increases the risk of early ischemic stroke recurrence, which is highest in the first days to weeks after the index event.

19. A 34-year-old woman presents in septic shock from a ruptured appendix. Laboratory results reveal: PT (prothrombin time) 28 seconds, INR 2.6, aPTT (activated partial thromboplastin time) 68 seconds, fibrinogen 72 mg/dL, D-dimer markedly elevated, and platelet count 44,000/mcL. She has active bleeding from IV sites and petechiae. The clinical diagnosis is DIC (disseminated intravascular coagulation — a syndrome of systemic coagulation activation causing simultaneous microvascular thrombosis and secondary fibrinolysis). Which of the following correctly describes the management of her hemostatic defects?

A) The primary treatment is source control and treatment of the underlying sepsis; FFP (fresh frozen plasma) is given to replace consumed clotting factors, cryoprecipitate is given to replace fibrinogen (target above 150 mg/dL), and platelet transfusion targets above 50,000/mcL with active bleeding; tranexamic acid (TXA) should generally be avoided because fibrinolysis in DIC is reactive and protective against microvascular thrombosis, and TXA suppression risks worsening organ ischemia
B) Tranexamic acid (TXA) 1 g IV should be given immediately to arrest the fibrinolysis driving the consumptive coagulopathy, as TXA is the first-line agent for all forms of DIC because it directly addresses the primary pathophysiological driver of factor depletion
C) Heparin infusion should be started at therapeutic doses to interrupt the cycle of systemic thrombin generation driving factor consumption, as anticoagulation is the cornerstone of DIC management regardless of whether the patient is actively bleeding
D) Four-factor PCC (4F-PCC) is preferred over FFP for factor replacement in DIC because it provides more concentrated factor restoration in a smaller volume and avoids the fluid overload associated with large-volume FFP transfusion in critically ill patients
E) Platelet transfusion should be given to a target of above 100,000/mcL because sepsis-associated DIC causes platelet function defects in addition to thrombocytopenia, and higher platelet counts are required to achieve adequate primary hemostasis in this setting

ANSWER: A

Rationale:

Option A is correct. DIC is a pathological syndrome driven by excessive systemic thrombin generation, which simultaneously consumes clotting factors and platelets (through microvascular thrombosis) and activates reactive secondary fibrinolysis (through plasminogen activation by endogenous tPA released from damaged endothelium). The management hierarchy is: (1) treat the underlying cause (sepsis source control in this case, as removing the trigger is the only definitive treatment); (2) replace consumed hemostatic components: FFP for broad factor replacement, cryoprecipitate to specifically correct fibrinogen (target above 150 mg/dL), and platelet transfusion for counts below 50,000/mcL with active bleeding. Antifibrinolytic agents such as TXA should generally be avoided in DIC because the fibrinolysis is reactive and serves to limit the extent of microvascular occlusion — inhibiting it risks extending organ ischemia. The exception is DIC in APL (acute promyelocytic leukemia), where primary hyperfibrinolysis predominates and TXA is beneficial before ATRA (all-trans retinoic acid) takes effect.

Option B: Option B is incorrect: TXA is contraindicated in most forms of DIC; routine antifibrinolytic therapy in DIC worsens outcomes by suppressing protective fibrinolysis — describing it as first-line therapy is clinically dangerous.
Option C: Option C is incorrect: heparin has a very limited role in DIC and is generally reserved for DIC with predominant thrombotic manifestations (purpura fulminans, acral ischemia) rather than the bleeding-predominant DIC seen here; starting therapeutic heparin in an actively bleeding patient with DIC can worsen hemorrhage.
Option D: Option D is incorrect: 4F-PCC contains factors II, VII, IX, and X and proteins C and S but does not contain fibrinogen or other plasma proteins in the proportions needed for DIC management; FFP, despite its volume, remains standard for broad factor replacement in DIC because it restores all coagulation proteins proportionally.
Option E: Option E is incorrect: the standard platelet transfusion target in DIC with active bleeding is above 50,000/mcL, not 100,000/mcL; the 100,000/mcL threshold is used for platelet transfusion in the context of CNS procedures or when platelet function is specifically tested as defective.

20. The PEITHO (Pulmonary Embolism Thrombolysis) trial evaluated thrombolysis in submassive PE — also called intermediate-risk PE, meaning hemodynamically stable patients with RV (right ventricular) dysfunction and elevated biomarkers (troponin). Which of the following correctly summarizes the trial's key findings and their clinical implication for the management of submassive PE?

A) The PEITHO trial showed that tenecteplase significantly reduced 30-day mortality in submassive PE with no increase in major bleeding, establishing systemic thrombolysis as the standard of care for all patients with intermediate-risk PE and any evidence of RV dysfunction
B) The PEITHO trial demonstrated that catheter-directed thrombolysis (CDT) was superior to systemic thrombolysis in submassive PE, establishing CDT as the preferred intervention for intermediate-risk patients with RV dysfunction and elevated troponin
C) The PEITHO trial showed no difference between tenecteplase and placebo in the composite primary outcome of hemodynamic decompensation or death, concluding that thrombolysis has no role in intermediate-risk PE
D) The PEITHO trial established that anticoagulation alone is sufficient for all patients with intermediate-risk PE, as tenecteplase failed to reduce any clinically meaningful outcomes and was associated with a higher rate of 3-month recurrence compared with placebo
E) The PEITHO trial demonstrated that tenecteplase reduced the composite primary outcome of hemodynamic decompensation or death within 7 days compared with placebo in hemodynamically stable patients with RV dysfunction and elevated troponin, but this benefit came at the cost of a significantly increased rate of major bleeding including stroke, supporting a conservative approach with anticoagulation alone as first-line therapy for most intermediate-risk PE patients

ANSWER: E

Rationale:

Option E is correct. The PEITHO trial (Meyer et al., NEJM 2014; n = 1,006) randomized hemodynamically stable patients with confirmed PE, RV dysfunction on echocardiography or CT, and a positive troponin T to tenecteplase versus placebo (with heparin anticoagulation in both arms). Tenecteplase significantly reduced the composite primary endpoint of hemodynamic decompensation or death within 7 days (2.6% vs. 5.6%), but at the cost of significantly increased major extracranial bleeding (6.3% vs. 1.2%) and stroke (2.4% vs. 0.2%, predominantly hemorrhagic). There was no significant difference in 30-day mortality. Because systemic thrombolysis in intermediate-risk PE trades a reduction in hemodynamic decompensation for a meaningful increase in life-threatening bleeding and stroke — with no mortality benefit — current guidelines recommend anticoagulation alone as standard therapy for most intermediate-risk patients. Thrombolysis is reserved for patients who deteriorate hemodynamically despite anticoagulation (rescue thrombolysis), and catheter-directed thrombolysis is an option for intermediate-high-risk patients to reduce systemic thrombolytic dose and bleeding exposure.

Option A: Option A is incorrect: PEITHO showed increased bleeding with tenecteplase and no 30-day mortality reduction; systemic thrombolysis is not the standard of care for all intermediate-risk PE.
Option B: Option B is incorrect: PEITHO evaluated systemic tenecteplase versus placebo — it did not compare CDT to systemic thrombolysis; CDT versus systemic thrombolysis is a separate evidence base.
Option C: Option C is incorrect: PEITHO did show a significant reduction in the composite primary outcome (hemodynamic decompensation or death); the trial's conclusion was not that thrombolysis has no role — rather, that the risk-benefit ratio favors anticoagulation alone for most intermediate-risk patients due to bleeding.
Option D: Option D is incorrect: tenecteplase did reduce the composite primary outcome and was not associated with higher 3-month recurrence; the trial's message was about bleeding risk, not lack of efficacy.

21. A 58-year-old man received enoxaparin (an LMWH — low molecular weight heparin) 1 mg/kg subcutaneously 6 hours ago for acute coronary syndrome. He now develops a major retroperitoneal bleed requiring immediate hemostatic intervention. Protamine sulfate is administered. Which of the following best describes the expected extent and mechanism of protamine's reversal activity against LMWH compared with its activity against UFH (unfractionated heparin)?

A) Protamine completely and predictably reverses LMWH anticoagulation, including both anti-Xa and anti-IIa activity, because LMWH and UFH share identical charge distributions and protamine forms complete ionic complexes with both preparations
B) Protamine completely neutralizes the anti-IIa (thrombin-inhibiting) activity of LMWH but only partially neutralizes anti-Xa activity (approximately 60 to 75%), because the shorter saccharide chains of LMWH have lower affinity for protamine binding compared with the longer chains of UFH
C) Protamine has no clinically meaningful activity against LMWH because LMWH molecules are too small to form stable ionic complexes with protamine; for enoxaparin reversal, idarucizumab must be substituted
D) Protamine reverses LMWH's anti-Xa activity completely but has no effect on anti-IIa activity, because LMWH exerts its anti-IIa effect through a protamine-resistant indirect mechanism involving a non-heparin cofactor
E) Protamine selectively reverses LMWH in patients with normal renal function but is ineffective in patients with renal impairment because LMWH accumulates in a protein-bound form that resists protamine neutralization when creatinine clearance falls below 30 mL/min

ANSWER: B

Rationale:

Option B is correct. Protamine sulfate reverses UFH through ionic neutralization of the polyanionic heparin polysaccharide chains. However, its activity against LMWH is less complete and less predictable. LMWH consists of shorter saccharide chains (mean molecular weight approximately 4,500 to 6,500 daltons) compared with UFH (mean molecular weight approximately 15,000 daltons). The shorter chains of LMWH have reduced affinity for protamine because protamine's positive charges bind most effectively to longer polysaccharide sequences. As a result, protamine completely neutralizes the anti-IIa (thrombin-inhibiting) activity of LMWH — which requires a longer heparin chain for the ternary AT-thrombin-heparin complex — but only partially neutralizes anti-Xa activity (approximately 60 to 75%), because the shorter pentasaccharide sequence required for anti-Xa activity retains some resistance to protamine neutralization. For enoxaparin given within 8 hours, the recommended dose is 1 mg protamine per 1 mg enoxaparin; a second dose of 0.5 mg/mg can be given if bleeding continues.

Option A: Option A is incorrect: protamine does not completely reverse LMWH's anti-Xa activity; describing complete and predictable reversal of both activities is factually inaccurate.
Option C: Option C is incorrect: protamine does have clinically meaningful activity against LMWH — it is the only available pharmacological reversal agent and partially reverses both anti-IIa and anti-Xa activity; idarucizumab is specific for dabigatran and has no activity against any heparin preparation.
Option D: Option D is incorrect: this reverses the correct pharmacology; it is anti-Xa (not anti-IIa) activity that is incompletely neutralized by protamine, and anti-IIa activity that is completely reversed.
Option E: Option E is incorrect: protamine's activity against LMWH is not modulated by renal function; the reduced reversal of anti-Xa activity is due to LMWH's molecular structure, not its renal accumulation.

22. A 77-year-old man with end-stage renal disease on hemodialysis and atrial fibrillation presents with a large intracranial hemorrhage. His nephrologist asks whether emergency hemodialysis could be used to remove his anticoagulant as an adjunct to reversal therapy. His anticoagulant is dabigatran. A colleague suggests switching all patients with renal failure and AF to rivaroxaban or apixaban because those drugs can be removed by dialysis if needed. Which of the following correctly describes the dialyzability of dabigatran compared with factor Xa inhibitors?

A) All DOACs (direct oral anticoagulants) including dabigatran, apixaban, and rivaroxaban are equally dialyzable because they are small molecules with similar molecular weights that are freely filtered at the glomerulus and readily removed by high-flux dialysis membranes
B) Neither dabigatran nor factor Xa inhibitors are dialyzable, as all DOACs are highly protein-bound (above 90%) and effectively sequestered from removal by hemodialysis or hemofiltration regardless of renal function
C) Dabigatran is approximately 35% protein-bound and is dialyzable by hemodialysis, which can remove a significant fraction of the drug in patients with high dabigatran body burden; factor Xa inhibitors (apixaban approximately 87%, rivaroxaban approximately 92 to 95% protein-bound) are not effectively removed by dialysis because their high protein binding limits their availability in plasma water
D) Rivaroxaban is the most dialyzable factor Xa inhibitor because it has the lowest protein binding of the class (approximately 50%), making it the preferred DOAC in patients with renal failure who might require emergent dialysis-based drug removal
E) Dabigatran's dialyzability is clinically irrelevant because idarucizumab always achieves complete reversal within minutes, making dialysis unnecessary even in patients on renal replacement therapy with very high dabigatran plasma concentrations

ANSWER: C

Rationale:

Option C is correct. The dialyzability of a drug by hemodialysis depends primarily on protein binding — only the unbound (free) fraction in plasma water crosses the dialysis membrane. Dabigatran is approximately 35% protein-bound, meaning a substantial free fraction is available for dialytic removal; hemodialysis can remove a clinically significant amount of dabigatran, particularly in patients with renal impairment where dabigatran accumulates because it is predominantly renally eliminated (approximately 80% unchanged in urine). In contrast, factor Xa inhibitors are highly protein-bound: apixaban approximately 87%, rivaroxaban approximately 92 to 95%, edoxaban approximately 55%. Their high protein binding means little free drug is available in plasma water, making them effectively non-dialyzable by conventional hemodialysis. This pharmacokinetic difference explains why dabigatran is specifically listed as dialyzable in prescribing information and guidelines for overdose management. The colleague's suggestion is exactly backwards — patients who might need dialysis-based drug removal would benefit from dabigatran (dialyzable), not from switching to factor Xa inhibitors.

Option A: Option A is incorrect: the claim that all DOACs are equally dialyzable ignores the large differences in protein binding between dabigatran and factor Xa inhibitors; molecular weight alone does not predict dialyzability when protein binding differences are this large.
Option B: Option B is incorrect: dabigatran is not highly protein-bound (it is approximately 35% protein-bound) and is dialyzable — describing all DOACs as non-dialyzable due to high protein binding is incorrect for dabigatran specifically.
Option D: Option D is incorrect: rivaroxaban is approximately 92 to 95% protein-bound, not 50% — it is among the more highly protein-bound DOACs and is not effectively dialyzable; this option inverts the correct pharmacological relationship.
Option E: Option E is incorrect: while idarucizumab achieves rapid and complete reversal in most patients, hemodialysis remains a valuable backup strategy in patients with very high dabigatran concentrations (particularly severe renal impairment with marked drug accumulation) if rebound anticoagulation occurs after idarucizumab clearance; dismissing dialysis as clinically irrelevant overstates the reliability of idarucizumab alone in all clinical scenarios.